Weight Regain After Stopping a GLP-1: What Studies Show

By the Strength from the Well Editorial Team · Evidence last reviewed September 2026 · Not reviewed by a licensed clinician (why we say that)

The short answer

In the trials that have looked at this directly, most people regain a large share of the weight they lost within a year of stopping a GLP-1 medication. In an extension of a major semaglutide trial, participants had regained about two thirds of their lost weight one year after stopping, and blood pressure and other measures largely returned toward where they started. This is what happens when a treatment that suppresses appetite is removed, not a sign that the medication damaged anything or that the person failed.

Key points

A one year follow up after a large semaglutide trial found participants regained roughly two thirds of the weight they had lost, with cardiometabolic improvements largely reversing alongside it.
A randomized withdrawal trial of tirzepatide found substantial regain in those switched to placebo, while those who stayed on treatment continued to lose.
Regain is not universal. A minority of people in these trials held onto more of their loss, and researchers do not yet fully understand why.
Obesity behaves like a chronic condition, which is why stopping treatment tends to reverse the effect, much as it does with blood pressure medication.
Muscle lost during rapid weight loss is not automatically regained during regain, so composition after a cycle is often worse than before.
Decisions about starting, continuing or stopping any of these medications belong with your prescriber, and stopping abruptly for cost or supply reasons is worth planning for in advance.

What the withdrawal studies actually found

The clearest evidence comes from studies that deliberately stopped the medication and watched what happened.

An extension of one of the large semaglutide weight management trials followed participants for a year after both the medication and the accompanying lifestyle support ended. On average, they regained about two thirds of the weight they had lost. Improvements in blood pressure, blood lipids and markers of blood sugar control moved back toward their starting values in step with the weight.

A separate randomized withdrawal trial with tirzepatide took a different approach. Everyone received the medication for an initial period and lost a substantial amount of weight. Participants were then randomly assigned either to continue or to switch to placebo. Those who continued lost more. Those switched to placebo regained a large portion of what they had lost over the following year.

An earlier trial using a similar withdrawal design with semaglutide found the same pattern: weight came back once the medication stopped, while it kept coming off in those who continued.

These are consistent results from good quality studies, and the conclusion they support is narrow and important. These medications work while they are being taken, and their effect on appetite does not persist once they are stopped.

Why the weight comes back

Two things are happening at once, and neither involves the medication having done harm.

The first is simply the removal of the drug's effect. These medications mimic gut hormones that signal fullness to the brain and slow stomach emptying. People taking them describe food noise going quiet, the background chatter about what to eat next fading. When the medication leaves the system, that signaling returns to baseline and appetite returns with it. Nothing was broken; a suppressant was withdrawn.

The second is the body's ordinary defense of lost weight, which applies to weight loss by any means. After substantial loss, resting energy expenditure falls by more than the smaller body alone would predict, and appetite hormones shift toward eating more, changes that can persist for a year or longer. Someone coming off a GLP-1 is facing that pressure without the tool that was offsetting it.

Put together, the surprise would be if weight did not return. That framing matters, because people who regain often describe it as proof that they were always going to fail. What it actually demonstrates is that the underlying condition was still there the whole time and was being treated rather than cured.

What else comes back

The regain is not only about weight. In the semaglutide extension, the improvements in blood pressure, triglycerides and glycemic markers largely reversed as weight returned. That is worth knowing because the health benefits of these medications track with the weight loss and, so far as this evidence shows, do not persist independently after stopping.

There is also a composition problem that the scale hides. Rapid weight loss on these medications includes a meaningful share of lean tissue, particularly when intake falls sharply and protein and resistance training are neglected. Regained weight, by contrast, tends to be disproportionately fat. Someone who returns to their starting weight after a cycle may have less muscle than they started with, at the same number on the scale.

This is the strongest practical argument for attending to protein and strength training throughout treatment rather than afterward. It is difficult to do during a phase when eating feels like a chore, and it is exactly when it counts.

Who holds onto more of the loss

The averages hide real variation. In these trials, some people regained nearly everything and some held onto a substantial share of their loss. Researchers have not established a reliable way to tell in advance who will be in which group, and the honest answer is that we do not fully understand the difference yet.

The factors that look plausible, based on what is known about weight maintenance generally rather than on GLP-1 specific trial evidence, include how much muscle was preserved, whether eating habits actually changed during treatment or only intake did, ongoing physical activity, sleep, and continued structured support after stopping.

That last point deserves emphasis. In the semaglutide extension, the lifestyle support ended when the medication did. People lost the drug and the scaffolding at the same moment. Whether keeping the scaffolding would have changed the outcome has not been directly tested, but it is a reasonable thing to arrange.

If you are thinking about stopping

This is a conversation for your prescriber, and nothing here is a recommendation to start, continue or stop anything. But a few things are worth walking in with.

Ask what the plan is for after. A great many people begin these medications with no discussion of an endpoint at all, which leaves the eventual stop, whether from cost, supply, side effects or a decision to move on, to happen without preparation.

Ask about cost and coverage before you are in a corner. Sudden stops driven by an insurance change or a price increase are common, and they are the worst version of this because they leave no time to prepare. Legitimate routes to reducing cost exist, including manufacturer programs, insurance appeals and discussions with a prescriber about alternatives. Products sold outside a prescriber and a licensed pharmacy are not one of those routes, whatever the marketing says.

And treat the months before and after a stop as a distinct project with its own plan: protein, resistance training, sleep, regular follow up, and honest expectations. Regain is the default. It is not the only possible outcome, and the parts you can influence are worth influencing.

Discuss an endpoint and a maintenance plan early, not at the last minute
Keep protein adequate and resistance train throughout, not only after stopping
Expect appetite to return and plan the food environment before it does
Keep whatever support structure you had rather than ending everything at once
Watch for a rebound in blood pressure and blood sugar, and keep follow up appointments

How to think about this without shame

Nobody describes a person whose blood pressure rises after stopping their blood pressure medication as having failed. The medication was doing something, it stopped doing it, and the underlying condition reasserted itself. Obesity is being understood in the same terms by the clinicians who treat it, and the withdrawal trials are among the strongest pieces of evidence for that view.

That reframing is not a consolation prize. It is a more accurate description of the mechanism, and it changes what the sensible next step is. The question after regain is not what is wrong with me. It is what treatment, structure and support does this condition need going forward, which is a question with actual answers.

If you have been through this cycle, you were not given a fair account of what to expect. Knowing what the trials found is not discouraging so much as clarifying: it tells you what you are actually up against, which is the only place a workable plan can start.

Common questions

Does stopping a GLP-1 damage your metabolism?

There is no evidence that these medications damage metabolism. Resting energy expenditure falls after substantial weight loss regardless of how the weight came off, and that adaptation is a response to being smaller rather than to the drug. Preserving muscle through protein and resistance training is the part of it you can influence.

Do people regain more than they lost?

In the published withdrawal studies, participants regained a large share of their loss but on average remained below their starting weight at the end of follow up. Overshooting past the original weight was not the typical finding. Individual results varied considerably in both directions.

Is a lower maintenance approach after stopping an option?

Continuing treatment at a reduced level is something clinicians discuss, and continued treatment clearly maintained weight better than stopping in the withdrawal trials. What the right approach is for any individual depends on their history, other conditions, side effects and cost, which makes it a prescriber conversation rather than something to decide from an article.

Why did the trials stop the lifestyle support at the same time?

Because the trials were designed to measure what happens when the treatment program ends, and the program included both parts. It does mean the results describe losing the medication and the support together. Whether keeping structured support in place would reduce regain has not been directly tested in this setting, which is an open question rather than a settled one.

Sources

This is information, not medical advice. Strength from the Well is an independent publisher. Nothing here is a diagnosis, a prescription, or a recommendation to start or stop any treatment. Talk to a clinician who knows your history before you act on anything you read here — including anything you read here that contradicts them.